Jefferies Financial Group Reiterates "Hold" Rating for CureVac (NASDAQ:CVAC)

Jefferies Financial Group reaffirmed their hold rating on shares of CureVac (NASDAQ:CVAC - Free Report) in a research note published on Friday, Marketbeat Ratings reports. They currently have a $5.00 price target on the stock, down from their previous price target of $7.00.

Other research analysts have also recently issued reports about the company. JMP Securities reiterated a "market outperform" rating and issued a $10.00 price objective on shares of CureVac in a report on Wednesday, May 28th. UBS Group reduced their target price on CureVac from $13.00 to $12.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th.

CureVac Trading Down 0.5%

Shares of CVAC traded down $0.03 during midday trading on Friday, reaching $5.57. The company had a trading volume of 4,834,011 shares, compared to its average volume of 800,115. CureVac has a 1-year low of $2.37 and a 1-year high of $5.72. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The firm has a 50 day simple moving average of $3.76 and a 200-day simple moving average of $3.48. The stock has a market cap of $1.25 billion, a PE ratio of 10.13 and a beta of 2.49.

CureVac (NASDAQ:CVAC - Get Free Report) last released its quarterly earnings data on Thursday, May 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.08). CureVac had a return on equity of 21.98% and a net margin of 20.72%. The firm had revenue of $0.94 million for the quarter, compared to analyst estimates of $4.27 million. Research analysts forecast that CureVac will post 0.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. GSA Capital Partners LLP purchased a new stake in shares of CureVac in the 1st quarter valued at approximately $853,000. BNP Paribas Financial Markets acquired a new stake in CureVac in the 4th quarter valued at approximately $585,000. Millennium Management LLC raised its position in CureVac by 10.3% in the first quarter. Millennium Management LLC now owns 1,816,984 shares of the company's stock valued at $5,033,000 after purchasing an additional 169,947 shares during the period. Two Sigma Investments LP purchased a new stake in CureVac in the fourth quarter valued at approximately $391,000. Finally, State of Wyoming acquired a new position in CureVac during the first quarter worth $317,000. Hedge funds and other institutional investors own 17.26% of the company's stock.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.